Epigral Limited has informed the Exchange regarding a press release dated May 02, 2026, titled "Press Release on Audited Financial Results Q4 & FY2026".
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Epigral reported its highest-ever Q4FY26 revenue of ₹736 crore, up 17% YoY and 22% sequentially, driven by 15% volume growth and improved plant utilization above 80%. PAT jumped 109% QoQ to ₹82 crore while EBITDA margin recovered to 23% from 17% in Q3FY26. For the full year FY2026, revenue dipped 1% to ₹2,542 crore due to a 4% volume decline in the first half from extended monsoon and planned maintenance. EBITDA stood at ₹567 crore with 22% margin, while ROCE fell to 16% from 25% in FY2025 due to lower utilization and higher raw material costs. Net Debt/EBITDA increased slightly to 0.9x. The Board proposed a final dividend of ₹5 per share. Capex of ₹394 crore was spent during the year on expansion projects for epichlorohydrin and CPVC capacity.
Strong Q4 recovery with margin expansion signals operational turnaround; however, FY2026 ROCE decline and higher leverage warrant monitoring. The proposed dividend and capex progress are positive for long-term shareholders.